Physician profile
Marguerite Root
NPI 1104391531
$2,107.95
in general payments reported to CMS, 2019-2025
21 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6.93 · 2023: $61.81 · 2024: $1,000 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $425.32 | 2024-2025 | |
| Abbvie INC. | $260.51 | 2023-2025 | |
| Ucb, INC. | $236.86 | 2024-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $195.15 | 2024-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $123.39 | 2024-2025 | Orencia |
| Janssen Biotech, INC. | $115.84 | 2024-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $107.01 | 2024-2025 | |
| Glaxosmithkline, LLC. | $102.07 | 2025 | Benlysta |
| Amgen INC. | $101.95 | 2024-2025 | Evenity, Prolia, Otezla |
| Mallinckrodt Hospital Products INC. | $90.77 | 2024-2025 | Acthar |
| Sobi, INC | $85.43 | 2024-2025 | |
| Sandoz INC. | $54.83 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.26 | 2024 | Ofev, Cyltezo |
| Supernus Pharmaceuticals, INC. | $30.59 | 2023 | Qelbree |
| Almatica Pharma LLC | $29.37 | 2024 | Teriparatide |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $25.33 | 2025 | |
| Lilly USA, LLC | $23.74 | 2024 | Taltz |
| Atland Pharmaceuticals, LLC | $20.58 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Mindera Corp | $18.77 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.25 | 2025 | Strensiq |
| Genentech USA, INC. | $6.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marguerite Root listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.